Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Relapsed/Refractory Classical Hodgkin's Lymphoma
NCT01877005Phase 2Completed
- Sponsor
- LYSARC
- Start
- Jul 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ruxolitinib in Hodgkin lymphoma (HL), sponsored by LYSARC. Started Jul 2013; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01877005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01877005.